Express Pharma

Cipla receives USFDA nod to market Lanreotide injection in US market

The company said it has received final approval for Lanreotide Injection from the US Food and Drug Administration (FDA)

0 723

Cipla yesterday said it has received approval from the US health regulator to market the Lanreotide injection, used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors, in the American market.

The company said it has received final approval for Lanreotide Injection from the US Food and Drug Administration (FDA).

The FDA approval is based on new drug application (NDA), it added.

The Lanreotide injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

- Advertisement -